• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Iterum Therapeutics plc

    9/9/24 6:15:02 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ITRM alert in real time by email
    DEFA14A 1 itrm-20240906.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    Iterum Therapeutics plc

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒

    No fee required.

     

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     


     

    ITERUM THERAPEUTICS PLC

    SUPPLEMENT TO NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS AND DEFINITIVE PROXY STATEMENT FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ORIGINALLY SCHEDULED TO BE HELD ON MONDAY, SEPTEMBER 9, 2024

     

     

    Iterum Therapeutics plc (the “Company”) intends to adjourn, without conducting any business, its extraordinary general meeting of shareholders ("EGM"), currently scheduled to take place on Monday, September 9, 2024, at 1.30 p.m. Irish time (8.30 a.m., U.S. Eastern Time) to allow the Company to solicit from its shareholders the additional proxies necessary to obtain approval of the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission ("SEC") on August 14, 2024 (the "Proxy Statement"). The EGM will reconvene on Monday, September 23, 2024, beginning at 1.30 p.m. Irish time (8.30 a.m., U.S. Eastern Time) at 3 Dublin Landings, North Wall Quay, Dublin 1, Ireland.

    The record date for the EGM continues to be the close of business on August 9, 2024.

    Shareholders who have previously submitted their proxy or otherwise voted on the proposals at the EGM and who do not want to change their vote need not take any action.

    You may change your vote and revoke your proxy prior to the EGM by doing any one of the following things:

    •
    submitting a new proxy by following the “Online” or “Phone” instructions on the enclosed proxy card at a date later than your previous vote but prior to the voting deadline (which is 4.59 a.m., Irish time on September 23, 2024 (11.59 p.m., Eastern Time on September 22, 2024)); or

    •
    signing another proxy card and either arranging for delivery of that proxy card by mail to our registered office prior to the start of the EGM, or by delivering that signed proxy card in person at the EGM; or

    •
    giving our Secretary a written notice before or at the EGM that you want to revoke your proxy; or

    •
    voting in person at the EGM.

    For questions relating to the voting of shares or to request additional or misplaced proxy voting materials, please contact the company secretary by email, in writing or by telephone as follows: [email protected], c/o Secretary, Iterum Therapeutics plc, Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2, Ireland, Phone: +353 1 6694820.

    As described in the Proxy Statement, a shareholder on the record date may use one of the following methods to vote before the reconvening of the adjourned EGM on September 23, 2024:

    1) You may vote over the Internet. You may vote your shares by following the "Online" instructions on your proxy card. If you vote over the Internet, you do not need to vote by telephone or complete and mail your proxy card. The internet voting facilities for eligible shareholders of record will close at 4.59 a.m., Irish time on September 23, 2024 (11.59 p.m., Eastern Time on September 22, 2024).

    2) You may vote by telephone. You may vote your shares by following the "Phone" instructions on your proxy card. If you vote by telephone, you do not need to vote over the Internet or complete and mail your proxy card. If you vote by telephone, your use of that telephone system, and specifically the entry of your pin number/other unique identifier, will be deemed to constitute your appointment, in writing and under hand, and for all purposes of the Irish Companies Act 2014, of each of David G. Kelly, Louise Barrett and Kevin Dalton as your proxy to vote your shares on your behalf in accordance with your telephone instructions. The telephone voting facilities for eligible shareholders of record will close at 4.59 a.m., Irish time on September 23, 2024 (11.59 p.m., Eastern Time on September 22, 2024).

    3) You may vote by mail. You may vote by completing, dating and signing the proxy card provided to you and promptly mailing it in the provided postage-paid envelope. If you vote by mail, you do not need to vote over the Internet or by telephone. The Company must receive the completed proxy card by 5.00 p.m., Irish time (12.00 p.m., Eastern Time), on September 20, 2024.

     


     

    4) You may vote in person. If you attend the EGM, you may vote by delivering your completed proxy card in person or you may vote by completing a ballot at the EGM. Ballots will be available at the EGM. You may obtain directions to the location of the EGM by requesting them in writing or by telephone as follows: c/o Secretary, Iterum Therapeutics plc, Fitzwilliam Court, 1st Floor, Leeson Close, Dublin 2, Ireland, Phone: +353 1 6694820.

    All proxies that have been or are executed and delivered by mail or in person or are otherwise submitted online or by telephone will be voted on the matter set forth in the previously delivered Notice of Extraordinary General Meeting of Shareholders in accordance with the shareholders’ instructions. However, if no choice was or is specified on a proxy as to the proposal, the proxy will be voted in accordance with the board of directors’ recommendation on the proposal as set forth in the Proxy Statement. All proxies have been and will be forwarded to our registered office electronically.

    If the shares you own are held in "street name" by a bank, broker or other nominee record holder, which we collectively refer to as "brokerage firms," your brokerage firm, as the record holder of your shares, is required to vote your shares according to your instructions. To vote your shares, you will need to follow the directions your brokerage firm provides you. Many brokerage firms also offer the option of voting over the Internet or by telephone, instructions for which, if available, would be provided by your brokerage firm on the voting instruction form that it delivers to you. Because most brokerage firms are member organizations of the New York Stock Exchange (“NYSE”), the rules of the NYSE will likely govern how your brokerage firm would be permitted to vote your shares in the absence of instruction from you. Under the current rules of the NYSE, if you do not give instructions to your brokerage firm, it may still be able to vote your shares with respect to certain “discretionary” items. Proposal No. 1, as set forth in the Proxy Statement, is considered a discretionary item under NYSE rules and therefore your brokerage firm may be able to vote on that item even if it does not receive instruction from you, provided it holds your shares in its name. In the event a bank, broker or other nominee record holder determines that it does not have authority or otherwise does not exercise discretionary authority to vote on Proposal No. 1, it may deliver “broker non-votes” for such shares.

    If your shares are held in "street name", you must bring an account statement from your brokerage firm showing that you are the beneficial owner of the shares as of the record date (August 9, 2024) to be admitted to the EGM. To be able to vote your shares held in street name at the EGM, you will need to request a “legal proxy” from the bank, broker or nominee.

    A copy of the Proxy Statement as previously filed with the SEC is available at no charge on the SEC website at www.sec.gov. In addition, copies of the Proxy Statement and other documents may be obtained free of charge by accessing the Company’s website at https://ir.iterumtx.com/.

     

     

     

    YOUR PARTICIPATION IS IMPORTANT - PLEASE VOTE TODAY!

     


    Get the next $ITRM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ITRM

    DatePrice TargetRatingAnalyst
    7/27/2021Sell → Hold
    Gabelli & Co.
    7/26/2021Buy → Neutral
    HC Wainwright & Co.
    More analyst ratings

    $ITRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dunne Michael W. bought $2,191 worth of Ordinary Shares (6,000 units at $0.37), increasing direct ownership by 3% to 241,001 units (SEC Form 4)

    4 - Iterum Therapeutics plc (0001659323) (Issuer)

    11/20/25 7:00:04 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dunne Michael W. bought $10,854 worth of Ordinary Shares (15,000 units at $0.72), increasing direct ownership by 7% to 235,001 units (SEC Form 4)

    4 - Iterum Therapeutics plc (0001659323) (Issuer)

    8/12/25 7:00:06 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Commercial Officer Coyne Christine

    4 - Iterum Therapeutics plc (0001659323) (Issuer)

    7/3/25 4:16:04 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ITRM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Iterum Therapeutics Provides Business Update

    DUBLIN and CHICAGO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum" or "we"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Market Access Update: Payor Reimbursement and Contracting Expands with Major PBM Agreement: ORLYNVAH™'s market access continues to accelerate. We have finalized a commercial contract with a Group Purchasing Organization that collaborates with manufacturers on behalf of one of the largest Pharmacy Benefit Managers ("PBMs") in the United States,

    12/17/25 8:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iterum Therapeutics Provides Business Update

    DUBLIN and CHICAGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum" or "we"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Market Access Update: Expanding Reimbursement Footprint: ORLYNVAH™'s access continues to grow—both with and without prior authorization or medical exception pathways, allowing coverage approval for many of the ORLYNVAH™ prescriptions written to date. Current coverage now reaches nearly 25% of insured lives in the U.S., with increasing adoption

    12/5/25 8:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iterum Therapeutics Provides Business Update

    DUBLIN, Ireland and CHICAGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update. Recent Events Specialty Distributor Now Stocked: ORLYNVAH™ is now available at McKesson, which will allow certain physicians the ability to procure the product directly from McKesson through this specialty distribution channel, consistent with their practice preferences.Sulopenem Susceptibility Disc FDA Cleared & Now Available to Order: Iterum has received

    11/24/25 8:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ITRM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dunne Michael W. bought $2,191 worth of Ordinary Shares (6,000 units at $0.37), increasing direct ownership by 3% to 241,001 units (SEC Form 4)

    4 - Iterum Therapeutics plc (0001659323) (Issuer)

    11/20/25 7:00:04 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dunne Michael W. bought $10,854 worth of Ordinary Shares (15,000 units at $0.72), increasing direct ownership by 7% to 235,001 units (SEC Form 4)

    4 - Iterum Therapeutics plc (0001659323) (Issuer)

    8/12/25 7:00:06 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dunne Michael W. bought $35,000 worth of Ordinary Shares (25,000 units at $1.40), increasing direct ownership by 28% to 113,754 units (SEC Form 4)

    4 - Iterum Therapeutics plc (0001659323) (Issuer)

    12/27/23 9:00:06 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ITRM
    SEC Filings

    View All

    SEC Form DEFA14A filed by Iterum Therapeutics plc

    DEFA14A - Iterum Therapeutics plc (0001659323) (Filer)

    1/26/26 4:30:02 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Iterum Therapeutics plc

    DEF 14A - Iterum Therapeutics plc (0001659323) (Filer)

    1/2/26 5:15:03 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Iterum Therapeutics plc

    PRE 14A - Iterum Therapeutics plc (0001659323) (Filer)

    12/23/25 5:15:04 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ITRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Iterum Therapeutics upgraded by Gabelli & Co.

    Gabelli & Co. upgraded Iterum Therapeutics from Sell to Hold

    7/27/21 11:35:29 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iterum Therapeutics downgraded by HC Wainwright & Co.

    HC Wainwright & Co. downgraded Iterum Therapeutics from Buy to Neutral

    7/26/21 12:19:14 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iterum Therapeutics upgraded by Gabelli & Co

    Gabelli & Co upgraded Iterum Therapeutics from Sell to Hold

    5/28/21 8:38:55 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ITRM
    Financials

    Live finance-specific insights

    View All

    Iterum Therapeutics Reports Third Quarter 2025 Financial Results

    --Commercially Launched ORLYNVAH™ in the United States in August 2025-- --Extended Cash Runway into Q2 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the quarter ended September 30, 2025. "We are thrilled to have launched ORLYNVAH™ in the United States in August 2025 for the treatment of uncomplicated urinary tract infections (uUTIs)," said

    11/14/25 7:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025

    DUBLIN, Ireland and CHICAGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Friday, November 14, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business. To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Ac

    11/7/25 8:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iterum Therapeutics Reports Second Quarter 2025 Financial Results

    -- Launch of ORLYNVAHTM Expected August 2025— --Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2025. "We are on track to launch ORLYNVAH™ this month for the treatment of uncomplicated urinary tract infections (uUTIs)," said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. "We're proud to introduce the first br

    8/5/25 7:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ITRM
    Leadership Updates

    Live Leadership Updates

    View All

    Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth

    DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer. In this role, Ms. Coyne will lead all commercial efforts for Iterum, including the upcoming launch of ORLYNVAH™ in the United States, as well as future commercialization activities across new products and markets. "We are delighted to welcome Christine to the Iterum leadership team at such a pivotal time for the company," said

    6/30/25 7:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer

    DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Sailaja Puttagunta, M.D., to the newly created position of Chief Medical Officer, where she will oversee global clinical development and regulatory initiatives for Iterum. "We are thrilled that Sailaja is back at Iterum given her strong industry and operational leadership at a time when oral sulopenem is re-entering the clin

    12/13/21 8:00:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors

    Patrick Heron to leave the Board DUBLIN, Ireland and CHICAGO, March 16, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Beth P. Hecht to the Company’s Board of Directors replacing Patrick Heron, who announced he would be leaving the Board, effective as of March 12, 2021. Ms. Hecht will also serve as a member of the Audit Committee and Compensation Committee of the Board. “I want to thank Patrick for his leade

    3/16/21 7:30:00 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ITRM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Iterum Therapeutics plc

    SC 13G/A - Iterum Therapeutics plc (0001659323) (Subject)

    11/14/24 7:54:21 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Iterum Therapeutics plc

    SC 13G - Iterum Therapeutics plc (0001659323) (Subject)

    11/14/24 3:31:48 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Iterum Therapeutics plc

    SC 13G - Iterum Therapeutics plc (0001659323) (Subject)

    1/31/24 4:55:45 PM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care